In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while reducing the …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of TG Therapeutics Inc (NASDAQ:TGTX) with a …
In a research report published Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) with a $22 …
In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Incyte Corporation (NASDAQ:INCY) with a price …
In a research report published Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Medivation Inc (NASDAQ:MDVN) with a price …
In a research report published Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on shares of Cytosorbents Corp (NASDAQ:CTSO) with a $25 price …
In a research report released yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), and reduced …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with some commentary on Neuralstem, Inc.(NASDAQ:CUR), after the biotech company released its second-quarter results and provided updates on its lead candidates.
Earlier today, Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with research reports on the DNA product development company Inovio Pharmaceuticals Inc (NASDAQ:INO), Biopharmaceutical company Repros Therapeutics Inc (NASDAQ:RPRX), …
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares popped 25.12% to $8.
